The quality of life role in patients with locally advanced breast cancer in the comprehensive evaluation of the complex neoadjuvant treatment efficacy
Keywordslocally advanced breast cancer, systemic polychemotherapy, endolymphatic polychemotherapy, selective intra-arterial polychemotherapy, quality of life
In recent years, breast cancer has been the most common cancer and the most common cause of disability among women in developed countries.
Determining the role of the quality of life parameter of patients during complex neoadjuvant treatment with the use of polychemotherapy in systemic (SPCT), endolymphatic (ELPCT) and selective intraarterial (SIAPCT) variants in patients with locally advanced breast cancer M.
The study was conducted on the basis of materials from 526 cases of MR RMZ T4A-DN0-2M0. The total sample was divided into three subgroups by parameter of route of neoadjuvant polychemotherapy (PCT): first control group (22 patients) - SPCT; the second control group (27 patients) - ELPCT; study group (41 patients) - SIAPCT.
Clinical effect with qualitative changes of local status and transfer of patients to the category of those with resectable tumors appeared in 46% of women of the first control group after 6 courses of SPCT, in 59% of the second control group after 4 courses of ELPHT and in 90% of the studied group after 3 courses SIAPCT.
After 3 courses of PCT, statistically better results of the experimental group were obtained in the positive dynamics of quality of life index in the amplitude and chronometric complex logran study as a result of neoadjuvant SIAPCT compared with the first (p<0.001) and second (p<0.05) control groups.
On the social well-being scale, the control group showed the best dynamics (p>0.05 inboth comparisons) with a high evaluation of restitution of work and social status.
On the symptom scales in the third group, after each course of polychemotherapy, symptoms of nausea and loss of appetite were observed at a significantly lower intensity compared to both control groups within 15 - 25 points of the group (p<0.05 inboth comparisons) and lasted 1 - 2 days less ( p<0.05 inboth comparisons).
Quality of life (QOL) research is a reliable, informative, and cost-effective method for assessing a patient's state of health at both group and individual levels. In cancer studies, QOL assessment is an important criterion for evaluating treatment effectiveness and is of prognostic value.
Mahvi D.A., Liu R., Grinstaff M.W., Colson Y.L., Raut C.P. Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies. CA Cancer J. Clin. 2018; 68 (6): 488-505.
Narod S.A. Personalised medicine and population health: breast and ovarian cancer. Hum. Genet. 2018; 137 (10): 769-778.
PDQ Screening and Prevention Editorial Board. PDQ Cancer Information Summaries. National Cancer Institute (US); Bethesda (MD): Dec 18, 2019. Breast Cancer Screening (PDQ®): Health Professional Version.
Parada H., Sun X., Tse C.K., Olshan A.F., Troester M.A. Lifestyle Patterns and Survival Following Breast Cancer in the Carolina Breast Cancer Study. Epidemiology. 2019; 30 (1): 83-92.
White A.J., Bradshaw P.T., Hamra G.B. Air pollution and Breast Cancer: A review. Curr. Epidemiol. Rep. 2018; 5 (2): 92-100.
Gucalp A., Traina T.A., Eisner J.R., Parker J.S., Selitsky S.R., Park B.H., Elias A.D., Baskin-Bey E.S., Cardoso F. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res. Treat. 2019; 173 (1): 37-48.
Rocque G.B., Williams C.P., Kenzik K.M., Jackson B.E., Azuero A., Halilova K.I., Ingram S.A., Pisu M., Forero A., Bhatia S. Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis. Cancer. 2018; 124 (21): 4231-4240.
Gautam S., Sylwestrzak G., Barron J., Chen X., Eleff M., Debono D., Nguyen A., Fisch M. Results From a Health Insurer's Clinical Pathway Program in Breast Cancer. J. Oncol. Pract. 2018; 15: JOP1800157.
Bottomley A., Therasse P., Piccart M., Efficace F., Coens C., Gotay C., Welnicka-Jaskiewicz M., Mauriac L., Dyczka J., Cufer T., Lichinitser M.R., Schornagel J.H., Bonnefoi H., Shepherd L.; European Organisation for Research and Treatment of Cancer Breast Cancer Group; National Cancer Institute of Canada; Swiss Group for Clinical Cancer Research. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol. 2005; 6 (5): 287-294.
Ghislain I., Zikos E., Coens C., Quinten C., Balta V., Tryfonidis K., Piccart M., Zardavas D., Nagele E., Bjelic-Radisic V., Cardoso F., Sprangers MAG, Velikova G., Bottomley A.; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group; Breast Cancer Group; EORTC Headquarters. Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. Lancet Oncol. 2016; 17 (7): 294-304.
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 90
Number of citations: 0